We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Antibody Conjugates for in-Vitro Imaging Applications Visualize and Quantify Proteins

By Biotechdaily staff writers
Posted on 31 May 2007
A new line of antibody conjugates for in vitro imaging applications is now available for biomedical researchers.

The Kodak X-Sight antibody conjugates for in vitro applications augment the line of conjugates for in vivo use that had been previously released by Carestream Health, Inc. More...
(New Haven, CT, USA).

The new antibody conjugates are designed for Western blotting applications, which use gel electrophoresis to separate proteins from a sample of cell or tissue based on molecular weight and size. After protein separation, a primary antibody targets the specific protein of interest. The Kodak X-Sight antibody conjugates then attach to the primary antibody and light up when excited by the appropriate wavelength of fluorescent light, thus allowing researchers to visualize and quantify the protein under investigation.

To minimize cross reactivity, the secondary antibodies have been affinity purified and are highly cross-absorbed. This treatment purportedly results in superior brightness, higher sensitivity, and excellent signal to noise results when compared to other commercially available conjugates. Conjugates are available conjugated to a variety of secondary antibodies in four distinct excitation and emission wavelengths ranging from just above ultraviolet (UV) to near infrared (IR), making them suitable for multiplex detection of proteins. While the antibody conjugates have been optimized for Kodak Image Station Systems instruments, they are also compatible with other commercially available digital imaging systems.

"The continuous introduction of novel Kodak X-Sight imaging agents is a sign of our commitment towards offering our customers a complete solution for their imaging needs. We are very excited about this proprietary product line with its demonstrated significant improvements in protein detection and other in-vitro applications over existing available products,” said Dr. Shahram Hejazi, president of Carestream Health's molecular imaging systems division.


Related Links:
Carestream Health

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.